Study of B013 plus paclitaxel for ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that stopped responding to platinum chemotherapy
- Your daily activity level is good: you can do most things without help (ECOG 0 or 1)
- You have at least one tumor that can be seen on scans
- You are willing to use effective birth control during the study and for 6 months after treatment
- You have not had previous treatment with B013 plus paclitaxel, and you don't have certain serious health issues (like recent infections, heart or lung disease, or other cancers in the last 5 years)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
This trial tests a new drug called BMX-001 combined with the chemotherapy drug paclitaxel for people with advanced ovarian or endometrial cancer that has come back or spread. The goal is to see if this combination can help control the cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Platinum-resistant Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.